Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2024: USD 0.04

Bafna Pharmaceuticals Limited EPS (Diluted) is USD 0.04 for the year ending March 31, 2024, a -36.02% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Bafna Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.06, a 100.24% change year over year.
Bafna Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.03, a -13.37% change year over year.
Bafna Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.03, a 102.42% change year over year.
Bafna Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2020 was USD -1.39, a -1,108.06% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Cleaning Supplies Composite Materials Cosmetics Drugstores & Retail Pharmacies Glass Plastics

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years